Market Intelligence, Clinical Progress, and High-Purity Reagents for Gastrointestinal and Oncological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TFF2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TFF2 ECD-Fc / Mutant Protein (Full-length & Trefoil Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TFF2 Products |
| Gene Delivery | TFF2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer (>10^8 TU/ml). |
View TFF2 Products |
| Benchmark Ab | Anti-TFF2 (Neutralizing Clone) Recombinant positive control for binding/inhibition assays. Sequence Verified. |
View TFF2 Products |
| Validator | TFF2 siRNA Set (3 target-specific sequences) For knockdown verification and specificity controls. |
View TFF2 Products |
| Related Target: TFF1 | TFF1 (Trefoil Factor 1) Family member for counter-screening and specificity validation. |
View TFF1 Products |
| Related Target: TFF3 | TFF3 (Trefoil Factor 3) Synergistic mucosal factor for cross-reactivity profiling. |
View TFF3 Products |
| Related Target: EGFR | EGFR (Epidermal Growth Factor Receptor) Primary signaling partner; TFF2 mediates mucosal healing via EGFR transactivation. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Counter Screening (TFF1/TFF3) / Trefoil Family Cross-reactivity | Homolog panel proteins strictly verified by mass spec and sequence analysis; Ortholog Panel (Human/Mouse/Rat TFF2) with >95% purity |
| Structural Integrity (Trefoil Motif) / Dimerization & Complex Formation | HEK293 Expressed ensuring native glycosylation and correct disulfide bond formation; SEC-HPLC verified monomer/dimer ratio |
| Receptor Binding Validation (e.g., EGFR interaction) | Active Fold Validation: SPR/BLI compatible format; Disulfide bond integrity confirmed by MS |
| Lack of Controls / Specificity | Clinical Benchmark Antibodies included; Validated siRNA + Isotype Control Antibodies; Sequence-verified ORF for rescue experiments |
| False Positives in Cell Assays | Valid sequence-verified siRNA included for precise specificity checks |
Live TFF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TFF2 therapeutics reveals a dual-track development paradigm. One track focuses on mucosal restitution and inflammatory bowel disease (IBD) leveraging recombinant TFF2 analogs, while the other investigates neutralizing monoclonal antibodies to counteract TFF2-mediated immune suppression in the tumor microenvironment (TME). As first-generation therapies reach the clinic, the next wave of R&D is targeting engineered TFF2 variants with enhanced EGFR binding affinity and modified glycosylation patterns for improved mucosal retention, as well as synergistic combinations with immune checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein | GI Biotechs, University Research Consortia | Mucositis, IBD, Gastric Ulcers | Structural Stability & Dimerization Analysis (Need SEC-verified monomer/dimer populations; native folded HEK293 proteins) |
| Monoclonal / Neutralizing Antibody | Oncology Innovators, Oncology Biotechs | Pancreatic Cancer, Gastric Cancer, Refractory Solid Tumors | Selectivity Assay (Need TFF1/TFF2/TFF3 cross-reactivity panels to avoid off-target GI toxicity) |
| Bispecific Antibody | Immuno-oncology Firms | Refractory Solid Tumors | Heterodimer Validation (Need High-purity ECD-Fc) |
| Peptide Mimetics | Academic Labs | Mucosal Protection | Stability Assay (Need high-concentration formulation testing with endotoxin-controlled protein) |
| Diagnostic / Biomarker | IVD Companies | Gastric Cancer Screening | Immunoassay Development (Need calibrator proteins with verified concentration by Amino Acid Analysis) |
Key Molecular Differentiation & Assay Strategy
1. Conformational Integrity & Dimerization
TFF2 function strictly depends on its head-to-tail dimer formation stabilized by inter- and intramolecular disulfide bonds. SEC-HPLC and non-reducing SDS-PAGE are essential. TarMart provides SEC-verified "predominantly dimer" batches with mass spectrometry disulfide mapping.
2. Subfamily Selectivity (TFF1/TFF2/TFF3)
Antibodies must discriminate between TFF2 and TFF1/TFF3 (P-domain homology >40%). Cross-binding ELISA/SPR using TarMart's TFF1/TFF2/TFF3 homologous protein panel (mass-spec verified, correct glycosylation) is critical to avoid off-target GI toxicity.
3. Receptor Binding (EGFR Engagement)
TFF2 mediates mucosal healing via EGFR transactivation. SPR/BLI assays using biotinylated TFF2 (TarMart) and high-purity EGFR extracellular domain are recommended. A431 cell-based phospho-ERK1/2 readout serves as functional validation.
4. Cross-Species Reactivity
For preclinical toxicology, cross-reactivity with rodent/cynomolgus TFF2 is needed. TarMart provides a three-species panel (human/mouse/rat) with mass-spec verification and consistent glycosylation patterns.